ClinicalTrials.gg
Not yet recruitingNCT07861139Updated Oct 9, 2026

Comparative Study of QL1209 and Perjeta® in Healthy Male Participants

A Phase 1 interventional study of QL1209 and US-Perjeta® in Breast Cancer, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Breast Neoplasms by Qilu Pharmaceutical Co., Ltd. — 6 open to participants now, 6 under way, 2 of them phase 3. Breast Neoplasms · Qilu Pharmaceutical Co., Ltd..

Planned enrollment
8th of 10
80 · median 225
Started
2026
with 1 other
Phase 1
3 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Breast Neoplasms by Qilu Pharmaceutical Co., Ltd., this one is the 8th largest by planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 10th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 10 studies in Breast Neoplasms by Qilu Pharmaceutical Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Breast Neoplasms by Qilu Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the similarity of pharmacokinetic (PK) parameters following a single intravenous infusion of QL1209 (Perjeta® biosimilar candidate) and Perjeta® (Pertuzumab) in healthy male participants.

Participants will receive a single intravenous infusion of QL1209 or US-Perjeta® 420 mg on D1, followed by observation until Day 99 postdose for PK, safety and immunogenicity assessments.

Read the detailed description

This is a randomized, double-blind, single-dose, parallel-controlled clinical trial to compare the PK profile of QL1209 and Perjeta® in healthy male participants. It is planned to enroll 80 healthy male participants and randomize them into the test group or reference group at a ratio of 1:1.

Participants will receive a single intravenous infusion of QL1209 or US-Perjeta® 420 mg on Day 1, followed by observation until Day 99 post-dose for PK, safety and immunogenicity assessments.

The study will include a screening period from Day 28 to Day 1. The participants will be admitted to the clinical study site on Day 1 and receive the QL1209 or US-Perjeta® on Day 1. The participants will remain in the in-patient department for observation until the assessment on Day 3 is completed. Participants will return to the clinical study site for out-patient visits till Day 99 or upon early withdrawal.

In the study, validated test methods will be used to determine QL1209/Pertuzumab concentrations in PK samples at different visit points after infusion administration. Non- compartmental models will be used to calculate PK parameters and perform statistical analysis. Anti-drug antibody (ADA) and titer in immunogenicity samples will be determined using a validated test method, and neutralizing antibody (Nab) will be further tested for ADA-positive samples.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Comparative Pharmacokinetic
  • QL2109
  • Perjeta
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male participants aged 18-55 (inclusive);
  2. Participants with body weight of ≥50 kg (inclusive)) and (BMI) of 18.5-32.0 kg/m2 (inclusive);
  3. Participants who voluntarily sign the written ICF;
  4. Participants who are able to communicate well with the investigator and complete the study as per the study protocol;
  5. Male participants who agree to use reliable (such as abstinence, contraceptive barrier, sterilization surgery) for themselves and their partners (such as birth control pills, contraceptive barrier, injection of the contraceptive medroxyprogesterone acetate or contraception by subcutaneous implantation), and agree not to donate sperm, during the study and within 7 months after infusion of the product.

Exclusion criteria

Exclusion Criteria:

  1. Trial participants with a history of or currently having any diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematological, immunological, psychiatric and metabolic disorders, or any other diseases that may interfere with the study results, or participants with clinically significant allergic reactions or allergic constitution, angioedema, interstitial pneumonitis or acute respiratory distress syndrome;
  2. Participants with abnormal vital signs (systolic blood pressure \< 90 mmHg or > 140 mmHg, diastolic blood pressure \< 50 mmHg or > 90 mmHg; heart rate \< 50 bpm or > 100 bpm) or clinically significant abnormalities in physical examination, and laboratory tests (participant to the judgment of clinicians), and those whose is beyond the normal range as shown by echocardiography; Adult males with a left ventricular ejection fraction (LVEF) outside the normal reference range of 52% to 72%, as defined by the American Society of Echocardiography (ASE), will be excluded;
  3. Any clinically relevant laboratory findings that, in the opinion of the Investigator, would preclude inclusion in the trial; including (ALT) >1.1 × (ULN), aspartate aminotransferase (AST) >1.2 × ULN, (total) >1.5 × ULN. Participants with estimated (eGFR) based on equation \< 90 mL/min/1.73 m2 will be excluded. If any of these tests are out-of-range, the tests can be repeated once;
  4. corrected for heart rate using Fridericia's correction (QTcF) > 450 msec.
  5. Participants with poor venous access;
  6. Participants with a history of allergy to the product (pertuzumab or any of its ), or, significant allergy to food, or other substances;
  7. Participants treated with anti- therapy or any antibody or other protein drug targeting the HER2 receptor;
  8. Participants who have taken any prescription or OTC drugs, including any herbal, and/or nutritional supplements (e.g. vitamins, mineral supplements or other health products) within 14 days before screening;
  9. Use of any monoclonal antibody within 3 months or 5 half-lives (whichever is longer) before administration;
  10. Use of investigational drugs within 30 days or 5 half-lives (whichever is longer) or discontinuation of monoclonal antibodies with unknown half-life within 6 months; prior to scheduled administration of the investigational drugs on Day 1 of this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    QL1209

    Drug: QL1209

  • Active comparator
    US-Perjeta®

    Drug: US-Perjeta®

Interventions

  • DrugQL1209

    A single intravenous infusion of QL1209 420 mg for 60 min ± 10 min.

  • DrugUS-Perjeta®

    A single intravenous infusion of US-Perjeta® 420 mg for 60 min ± 10 min.

This study also gives Pertuzumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. AUC0-∞

    Area under the serum concentration-time curve from time 0 to infinity

    Time frame: up to 99 days

07

Study locations

No study locations are listed for this record.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 6 months is below that.

Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2027
CompletionEst.
Sep 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 2 updates
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: conditions
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07861139
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Anne Monroe, MD
Contact
anne.monroe@pharmaron-us.com
240-673-0500 ext. 1716
James Phillips, MHCI
Contact
James.Phillips@pharmaron-us.com
240-673-0500 ext. 1750

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion